Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET James Markmann - Corporate Participant Michael ...

Women who replaced their lunchtime diet beverage with water had greater weight loss and achieved diabetes remission compared ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction ...

Diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments such as ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s compe ...

Chinese biotech firm Hangzhou Sciwind Biosciences is stepping into the high-stakes global obesity drug race, with its ...

Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target ...